Can 0.025-inch Guidewire VisiGlideTM become a Standard in the ERCP-related Procedures? VIP Study

Aims: With the progress of development of 0.025-inch guidewire (GW), various treatments with 0.025-inch GW have become possible. To date, however, there has been no multicenter cooperative prospective study using 0.025-inch GW VisiGlideTM as the versatile GW. This time, we decided to examine the result of the use of 0.025-inch GW VisiGlideTM as the first choice in the endoscopic retrograde cholangiopancreatography (ERCP)-related procedure without selecting the patient in a multicenter cooperative prospective study.
Study Design: Multi-center single arm prospective study.
Methodology: The 0.025-inch GW VisiGlideTM was used in the patients with biliopancreatic diseases requiring ERCP as the first choice to examine the accomplishment rate of procedure and the incidence of accidental symptom.
Results: The accomplishment rate of procedure was 92.8% (180/194). The accidental symptoms of ERCP-related procedures were observed at 4.6% (9/194) and GW perforation was observed as a GW-related accidental symptom at 2.1% (4/194) but all the accidental symptoms resolved conservatively.
Conclusion: The 0.025-inch GW VisiGlideTM has a high accomplishment rate of procedure and a low incidence of accidental symptom in its use in the ERCP-related procedure, and it was suggested that it may be available as a versatile GW. Clinical Trial Registry (UMIN000008180).